Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 29 min 27 sec ago

Synta Names Anne Whitaker Chief Executive Officer

Wed, 08/06/2014 - 12:16
LEXINGTON, Mass.--(Healthcare Sales & Marketing Network)--Synta Pharmaceuticals Corp. (SNTA) today announced that Anne Whitaker will join the Company as President, Chief Executive Officer and a member of the Company’s Board of Directors effective September...
Biopharmaceuticals, Personnel
Synta Pharmaceuticals

Akebia Therapeutics Announces Expansion of Management Team

Wed, 08/06/2014 - 12:13
Key additions will help drive strategic growth and advance lead clinical programs CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-indu...
Biopharmaceuticals, Personnel
Akebia Therapeutics, hypoxia-inducible factor

FDA Approves the SynCardia Total Artificial Heart With SynHall Valves

Tue, 08/05/2014 - 17:01
SynCardia Systems, Inc., now controls last key component in heart manufacturing TUCSON, Ariz., Aug. 5, 2014 -- (Healthcare Sales & Marketing Network) -- SynCardia Systems, Inc. received approval July 2, 2014 from the United States Federal Drug Administ...
Devices, Cardiology, FDA
SynCardia Systems, Total Artificial Heart, SynHall valve

IsoRay's Cesium-131 Isotope Produces Excellent Results in Treating Metastatic Brain Cancer as Published in the Journal of Neurosurgery

Tue, 08/05/2014 - 16:57
100% Local (Resection Cavity) Freedom From Progression With 19.3 Month Median Follow-Up RICHLAND, WA--(Healthcare Sales & Marketing Network) - IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radi...
Devices, Neurosurgery, Oncology
IsoRay, Cesium-131, brachytherapy, brain cancer, radiotherapy

EDAP Comments on FDA Panel Vote

Tue, 08/05/2014 - 16:52
Responds to Gastroenterology and Urology Devices Panel Vote on Ablatherm-HIFU for Treatment of Prostate Cancer LYON, France, Aug. 5, 2014 -- (Healthcare Sales & Marketing Network) -- EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, today...
Devices, Oncology, FDA
EDAP TMS, Ablatherm, high-intensity focused ultrasound, prostate cancer

CardioMEMS Heart Failure Monitoring System Receives Approval from CMS for New Technology Add-On Payment

Tue, 08/05/2014 - 16:48
St. Jude Medical’s CardioMEMS HF System demonstrates our commitment to delivering high-quality, innovative solutions that reduce health care costs and improve outcomes for patients ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. Jude Medic...
Devices, Cardiology, Reimbursement
St. Jude Medical, CardioMEMS, pulmonary artery pressure

Alzheon Appoints Renowned Industry Leader, Jean-Pierre Sommadossi, PhD, to Board of Directors

Tue, 08/05/2014 - 16:44
LEXINGTON, Mass.--(Healthcare Sales & Marketing Network)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that it has appointed Jean-Pierre Sommadossi, PhD, to the company’s Board of Dire...
Biopharmaceuticals, Neurology, Personnel
Alzheon, ALZ-801, Alzheimer’s disease

MELA Sciences Names Michael R. Stewart to Board of Directors

Tue, 08/05/2014 - 16:41
Stewart Brings to MELA a Wealth of Dermatological Medical Device Expertise Across All Aspects of the Business IRVINGTON, N.Y., Aug. 5, 2014 -- (Healthcare Sales & Marketing Network) -- MELA Sciences, Inc. (MELA), developer of the MelaFind(R) system, an ...
Devices, Diagnostics, Oncology, Dermatology, Personnel
MELA Sciences, MelaFind, melanoma

Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market

Tue, 08/05/2014 - 12:25
QUÉBEC CITY, Aug. 5, 2014 -- (Healthcare Sales & Marketing Network) - Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) (the "Company") today announced a strategic co-promotion services agreement with ASCEND Therapeutics® US, LLC, ("ASCEND...
Biopharmaceuticals, Distribution
Aeterna Zentaris, ASCEND Therapeutics, EstroGel, Macrilen

Boston Therapeutics Expands Medical Advisory Board

Tue, 08/05/2014 - 12:20
Noted Diabetes Experts Meng H Tan, M.D., Philip Raskin, M.D., and Charles M. Clark, Jr., M.D. to Serve as Medical Advisory Board Members MANCHESTER, NH--(Healthcare Sales & Marketing Network)) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Ther...
Biopharmaceuticals, Personnel
Boston Therapeutics

TesoRx Closes $10M in Funding, Secures Key Patent and Hires Renowned Urologist as Chief Medical Officer

Tue, 08/05/2014 - 12:15
MENLO PARK, Calif., Aug. 5, 2014 -- (Healthcare Sales & Marketing Network) -- TesoRx Pharma, LLC., a specialty pharmaceutical company focused on rapidly developing and commercializing products in specialty and niche markets, announced today that it has cl...
Biopharmaceuticals, Personnel, Venture Capital
TesoRx Pharma

Caris Molecular Intelligence(TM) Identifies Key Biomarkers of Clinical Benefit and Resistance to Chemotherapy through Multi-Technology Tumor Profiling

Tue, 08/05/2014 - 12:11
Peer-Reviewed Case Study from Fox Chase Cancer Center Demonstrates Value of Company's Unique Approach to Precision Medicine to Uncover Critical Treatment Insights IRVING, Texas, Aug. 5, 2014 -- (Healthcare Sales & Marketing Network) -- Caris Life Scien...
Diagnostics, Oncology
Caris Life Sciences, Molecular Intelligence, tumor profiling

Akers Appoints New Vice President of International Sales and Marketing to Build International Business

Tue, 08/05/2014 - 12:04
THOROFARE, N.J., Aug. 5, 2014 -- (Healthcare Sales & Marketing Network) -- Akers Biosciences, Inc. (AKER) (AKR.L) (the "Company" or "Akers"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announ...
Diagnostics, Personnel
Akers Biosciences

Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Tue, 08/05/2014 - 12:01
SAN DIEGO, Aug. 5, 2014 -- (Healthcare Sales & Marketing Network) -- Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Genoa fo...
Biopharmaceuticals, FDA
Genoa Pharmaceuticals, pirfenidone, Esbriet, Idiopathic Pulmonary Fibrosis

RestorGenex Appoints Mark Weinberg, MD, MBA Senior Vice President of Clinical Development

Mon, 08/04/2014 - 10:54
CHICAGO--(Healthcare Sales & Marketing Network)-RestorGenex Corporation (RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women’s health, announced today the appointment of Mark Weinbe...
Biopharmaceuticals, Personnel
RestorGenex

Hill-Rom Completes Acquisition of Trumpf Medical

Fri, 08/01/2014 - 17:00
CHICAGO, Aug. 1, 2014 -- (Healthcare Sales & Marketing Network) -- Hill-Rom Holdings, Inc. (HRC) today announced that it has completed its approximately $250 million purchase of Trumpf Medical, the medical unit of the privately held TRUMPF Group. The tran...
Devices, Surgery, Mergers & Acquisitions
Hill-Rom, Trumpf Medical

FDA Approves Boehringer Ingelheim's Striverdi(R) Respimat(R) (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

Fri, 08/01/2014 - 14:25
RIDGEFIELD, Conn., Aug. 1, 2014 -- (Healthcare Sales & Marketing Network) -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved Striverdi® Respimat® (olodaterol) Inhalation Spray 5 mcg as a long-term...
Biopharmaceuticals, FDA
Boehringer Ingelheim, Striverdi Respimat, olodaterol, COPD

European Commission Grants Orphan Drug Designation to Soliris(R) (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)

Fri, 08/01/2014 - 14:16
CHESHIRE, Conn.--(Healthcare Sales & Marketing Network)--Alexion Pharmaceuticals (ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis...
Biopharmaceuticals, Regulatory
Alexion Pharmaceuticals, Soliris, eculizumab, Myasthenia Gravis

MEDICREA’s K-JAWS(R) Obtains FDA Approval for Its Marketing in the United States

Fri, 08/01/2014 - 13:49
LYON, France--(Healthcare Sales & Marketing Network)--The MEDICREA Group: (ALMED.PA) (FR0004178572-ALMED), which specializes in the development of innovative surgical technologies for the treatment of spinal pathologies and is listed on Alternext - Paris, ...
Devices, Neurosurgery, Orthopaedic, FDA
MEDICREA, K-JAWS, Cervical Compression Staple

American Shared Hospital Services Announces Proposed 2015 CMS Gamma Knife and Proton Therapy Reimbursement Rates

Thu, 07/31/2014 - 15:13
SAN FRANCISCO--(Healthcare Sales & Marketing Network)--AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that the Centers for Medi...
Devices, Oncology, Reimbursement
American Shared Hospital Services, Gamma Knife, proton therapy, radiotherapy

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong